Re: personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy

Comment

Arnold L Potosky et al. J Natl Cancer Inst. 2011.

. 2011 Dec 21;103(24):1899-901; author reply 1901-3.

doi: 10.1093/jnci/djr439. Epub 2011 Oct 28.

No abstract available

Comment on

Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy.
Kuderer NM, Lyman GH. Kuderer NM, et al. J Natl Cancer Inst. 2011 Jun 22;103(12):910-3. doi: 10.1093/jnci/djr195. Epub 2011 Jun 13. J Natl Cancer Inst. 2011. PMID: 21670422 Free PMC article. No abstract available.

1. Potosky AL, Malin JL, Kim B, et al. Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes. J Natl Cancer Inst. 2011;103(12):979–982. - PMC - PubMed
1. Kuderer NM, Lyman GH. Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy. J Natl Cancer Inst. 2011;103(12):910–913. [Erratum in: J Natl Cancer Inst. 2011;103(16):1278] - PMC - PubMed
1. Crawford J, Althaus B, Armitage J, et al. Myeloid growth factors. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007;5(2):188–202. - PubMed
1. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24(19):3187–3205. - PubMed
1. Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8–32. - PubMed